Haemonetics (HAE) Revenue (2009 - 2026)

Haemonetics' Revenue history runs 18 years deep, the most recent figure standing at $346.4 million for Q1 2026.

• On a quarterly basis, Revenue rose 4.76% year-over-year to $346.4 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 1.97% decrease from a year earlier, with the FY2026 full-year figure at $1.3 billion, down 1.97% from the prior year.
• Revenue improved to $346.4 million in Q1 2026 per HAE's latest filing, from $339.0 million in the prior quarter.
• Across five years, Revenue topped out at $348.5 million in Q4 2024 and bottomed at $259.8 million in Q1 2022.
• The 5-year median for Revenue is $324.4 million (2025), against an average of $316.5 million.
• Across the five-year window, Revenue advanced 24.01% in 2022 and declined 5.27% in 2025, its largest moves.
• Year by year, Revenue stood at $305.3 million in 2022, then climbed by 10.14% to $336.2 million in 2023, then rose by 3.66% to $348.5 million in 2024, then fell by 2.75% to $339.0 million in 2025, then grew by 2.18% to $346.4 million in 2026.
• Per Business Quant, the three latest HAE Revenue figures stand at $346.4 million (Q1 2026), $339.0 million (Q4 2025), and $327.3 million (Q3 2025).